AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP)

The protocol includes 3 parts:

• Part A: first-in-human single ascending dose (SAD) study in healthy volunteers

• Part B: multiple ascending dose (MAD) study with 2 weeks of treatment in healthy volunteers

• Part C: open-label MAD study with a total treatment duration of 3 months in patients with cHP.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Amolyt Pharma

Criteria

Main inclusion criteria

• Part A: healthy male volunteers aged 18 to 60 years inclusive with a Body mass index of 19 to 28 kg/m2

• Part B: healthy male and female volunteers (non-child bearing potential) aged 18 to 60 years inclusive with a Body mass index of 19 to 28 kg/m2

• Part C:

1. Male and female patients aged 18 to 75 years inclusive

2. History of cHP for ≥12 months at the time of screening with documentation of two measurements of serum calcium and parathyroid hormone (PTH).

3. Requirement for therapy with calcitriol ≥0.25 μg per day or alphacalcidol ≥0.50 μg per day (both are active vitamin D supplements), and requirement for supplemental oral calcium treatment ≥1000 mg per day over and above normal dietary calcium intake at baseline assessments.

Main exclusion criteria

• Parts A and B:

1. Clinically significant abnormal lab values, as judged by the investigator

2. Using tobacco products with 3 months prior to first drug administration

3. History of alcohol abuse or drug addiction

• Part C

1. Known history of autosomal-dominant hypocalcemia (ADH resultingfrom gain-of-function calcium-sensing receptor [CaSR] or GNA11 mutations) or pseudohypoparathyroidism (impaired responsiveness to PTH)

2. Any current disease that might affect calcium metabolism or calciumphosphate homeostasis other than HP

3. Use of medications such as loop and thiazide diuretics, raloxifene hydrochloride, lithium, methotrexate, cardiac glycosides (e.g., digoxin or digitoxin) or systemic corticosteroids within 4 weeks prior to start of treatment.

4. Previous treatment with PTH-like drugs, including PTH(1-84), PTH(1-34), or abaloparatide, within 3 months prior to screening.